Literature DB >> 21264872

Target epitopes of HTLV-1 recognized by class I MHC-restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders.

Tomohiro Kozako1, Masaki Akimoto, Shingo Toji, Yohann White, Susumu Suzuki, Takehiro Arima, Yukio Suruga, Kakushi Matsushita, Hiroshi Shimeno, Shinji Soeda, Ryuji Kubota, Shuji Izumo, Kimiharu Uozumi, Naomichi Arima.   

Abstract

Human T-cell lymphotropic virus type I (HTLV-1) causes adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The different patterns of clinical diseases are thought to be linked to immunogenetic host factors. A variety of autoimmune diseases, such as Sjögren's syndrome, have been reported in persons infected with HTLV-1, although the precise relationship between these disorders and HTLV-1 infection remains unknown. There is no report on the repertoire of HTLV-1-specific CD8+ T-cells in HAM/TSP patients or carriers with autoimmune diseases, both characterized by an abnormal immune state. In this study, to characterize HTLV-1-specific CD8+ T-cells in asymptomatic HTLV-1 carriers, HAM/TSP patients and carriers with autoimmune diseases, we examined the frequency and diversity of HTLV-1-specific CD8+ T-cells using HTLV-1 tetramers. HTLV-1 Env-specific CD8+ T-cells were significantly more frequent in HAM/TSP and carriers with autoimmune diseases compared with asymptomatic HTLV-1 carriers, while the frequency of HTLV-1 Tax-specific CD8+ T-cells was not significantly different among them. CD8+ cells binding to HTLV-1 Tax tetramers in carriers with autoimmune diseases were significantly reduced compared with HAM/TSP patients. This study demonstrates the importance of CD8+ T-cells recognizing HTLV-1 Env-tetramers in HAM/TSP patients and carriers with autoimmune diseases, thereby suggesting that the diversity, frequency and repertoire of HTLV-1 Env-specific CD8+ T-cell clones may be related to the hyperimmune response in HAM/TSP and carriers with autoimmune diseases, although different immunological mechanisms may mediate the hyperimmunity in these conditions.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264872     DOI: 10.1002/jmv.21985

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine.

Authors:  Divya Sagar; Shet Masih; Todd Schell; Steven Jacobson; Joseph D Comber; Ramila Philip; Brian Wigdahl; Pooja Jain; Zafar K Khan
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

2.  Liposomes and nanotechnology in drug development: focus on oncotargets.

Authors:  Tomohiro Kozako; Naomichi Arima; Makoto Yoshimitsu; Shin-Ichro Honda; Shinji Soeda
Journal:  Int J Nanomedicine       Date:  2012-09-14

3.  Novel small-molecule SIRT1 inhibitors induce cell death in adult T-cell leukaemia cells.

Authors:  Tomohiro Kozako; Takayoshi Suzuki; Makoto Yoshimitsu; Yuichiro Uchida; Ayako Kuroki; Akiyoshi Aikawa; Shin-ichiro Honda; Naomichi Arima; Shinji Soeda
Journal:  Sci Rep       Date:  2015-06-19       Impact factor: 4.379

Review 4.  A role for an HTLV-1 vaccine?

Authors:  Lee Ratner
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

5.  Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals.

Authors:  Aline C A Mota-Miranda; Fernanda K Barreto; Maria F C Amarante; Everton Batista; Joana P Monteiro-Cunha; Lourdes Farre; Bernardo Galvão-Castro; Luiz C J Alcantara
Journal:  Virol J       Date:  2013-03-06       Impact factor: 4.099

6.  Stability of the HTLV-1 glycoprotein 46 (gp46) gene in an endemic region of the Brazilian Amazon and the presence of a significant mutation (N93D) in symptomatic patients.

Authors:  Maria de Nazaré do Socorro de Almeida Viana; Akim Felipe Santos Nobre; Edivaldo Costa; Ingrid Christiane Silva; Bruna Teles Pinheiro; Cássia Cristine Costa Pereira; Louise de Souza Canto Ferreira; Danilo Souza de Almeida; Marcos William Leão de Araújo; Mariza da Silva Borges; Carlos Araujo da Costa; Edna Aoba Yassui Ishikawa; Stephen Francis Ferrari; Maísa Silva de Sousa
Journal:  Virol J       Date:  2018-05-02       Impact factor: 4.099

Review 7.  TCR-like antibodies in cancer immunotherapy.

Authors:  Qinghua He; Zhaoyu Liu; Zhihua Liu; Yuxiong Lai; Xinke Zhou; Jinsheng Weng
Journal:  J Hematol Oncol       Date:  2019-09-14       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.